Nachrichten zur Atea ASA Aktie

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…

Presentation of 1[st] quarter 2023 results

Atea ASA will present its 1[st] quarter 2023 financial results on Thursday, 27 April 2023 at 08:00 CEST. The presentation will…

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study,…

Key information relating to cash dividend to be paid by Atea ASA

The Board of Atea ASA has proposed a cash dividend with the following key details: Dividend amount: …

Atea ASA 2022 Annual Report in ESEF format

The company publishes its annual financial statements in European Single Electronic Format (ESEF), available as an attachment to this release. Compared to…

Notice of Annual General Meeting

The Annual General Meeting will be held on Thursday 27 April 2023 at 09:30 a.m. at Thon Hotel Vika Atrium,…

Atea Norway signs large public sector frame agreement

Atea has today signed a large public sector frame agreement with the Norwegian state procurement authority (DFØ). The frame agreement…

Grant of share options to primary insiders in Atea ASA

On 16 March 2023, key employees in the Atea Group were granted share options in Atea ASA. The following primary insiders…

Chairman Ib Kunøe to step down from Board

Chairman Ib Kunøe has notified his intention to retire from the Board of Directors of Atea ASA following the Annual…

GlobalConnect appoints Annette Otto as SVP of People and Culture

Nordic digital infrastructure and connectivity provider GlobalConnect appoints Annette Otto as its new SVP of People and Culture. Otto comes…

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…

Form 10-K Atea Pharmaceuticals, For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea Pharmaceuticals GAAP EPS of -$0.41 beats by $0.04

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions...…

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…